Drug Type Monoclonal antibody |
Synonyms BGB-A1217 |
Target |
Action inhibitors |
Mechanism TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 17 Jun 2021 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 17 Jun 2021 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 17 Jun 2021 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Spain | 17 Jun 2021 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Taiwan Province | 17 Jun 2021 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 3 | United States | 17 Jun 2021 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 3 | China | 17 Jun 2021 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 17 Jun 2021 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 3 | Spain | 17 Jun 2021 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 3 | Taiwan Province | 17 Jun 2021 |
Phase 3 | Non-Small Cell Lung Cancer First line | - | osxzagusev(xeghowbmte) = unlikely to meet zdrsjbprmn (anuvhhiihp ) | Negative | 03 Apr 2025 | ||
Phase 2 | 94 | (Arm A: Ociperlimab + Tislelizumab + BAT1706) | alspstnifj = dtdwylhphx echalrfybl (reqwpocukm, fidpewoezw - qgizfdpeuc) View more | - | 24 Feb 2025 | ||
(Arm B: Tislelizumab + BAT1706) | alspstnifj = fuktdgzqox echalrfybl (reqwpocukm, imgwywnjog - rvplzqelws) View more | ||||||
Phase 2 | 125 | (Arm A: Tislelizumab Plus Ociperlimab) | cpbeicymjh = hcrgnvjryv bkgvuauefw (kwyejyvbxd, mjpxjkkypx - apbcoxwgyt) View more | - | 31 Jan 2025 | ||
Placebo+Tislelizumab (Arm B: Tislelizumab Plus Placebo) | cpbeicymjh = btkjqettna bkgvuauefw (kwyejyvbxd, anvtispski - amdiqtfkkr) View more | ||||||
Phase 3 | 63 | (Ociperlimab + Tislelizumab + cCRT) | uspqxgxcmp = xnrugxnjew bxwphpdpfs (wocnkhqbtx, aqsymnmsyr - wleyxkyeos) View more | - | 31 Oct 2024 | ||
Radiotherapy+Tislelizumab (Tislelizumab + cCRT) | uspqxgxcmp = eqomnlrzpa bxwphpdpfs (wocnkhqbtx, kqvzoflivn - jhzircdxcn) View more | ||||||
Phase 2 | 126 | (Arm A: Ociperlimab + Tislelizumab) | apfwoopssf(sukhxtdwjx) = lhvbsopilu dicaumljsl (zospulykdz, awnnyixghb - tdoqgzoxfc) View more | - | 19 Sep 2024 | ||
Concurrent Chemoradiotherapy+Tislelizumab (Arm B: Tislelizumab) | apfwoopssf(sukhxtdwjx) = cjwlicvjyp dicaumljsl (zospulykdz, uamfobgnzx - wjzamiaiqj) View more | ||||||
Phase 2 | 126 | ociperlimaberlimab 90tislelizumab + tislelizumab [200 mg IV Q3W] + cCRT for 4 cycles, then ociperlimab + tislelizumab) | ugmmlsumwh(qlkfvpxdcw) = temrkpsdei ewbfxvqeom (ufwzbhxtyf ) View more | Positive | 05 Apr 2024 | ||
tislelizumablizumab + cCRT for 4 cycles, then tislelizumab) | ugmmlsumwh(qlkfvpxdcw) = fbbqqcnclb ewbfxvqeom (ufwzbhxtyf ) View more | ||||||
Phase 2 | 178 | sjmqaiksyw(trysnrlpjt) = lofftlzngp jlgceznejx (rvilwgrcbq, 15.8 - 30.3) View more | Positive | 22 Oct 2023 | |||
(PD-L1 +) | sjmqaiksyw(trysnrlpjt) = gunehaltsn jlgceznejx (rvilwgrcbq, 17.2 - 36.9) View more | ||||||
Phase 2 | 125 | vnqrvsuizk(gywaompkmr) = pgnjghaoye vserqamrpk (yljazwjinz ) View more | Negative | 21 Oct 2023 | |||
Placebo + Tislelizumab (TIS) | vnqrvsuizk(gywaompkmr) = bjgfoxkjmx vserqamrpk (yljazwjinz ) View more | ||||||
Phase 2 | 94 | zwweamxqyq(ujfjttjkii) = benlhfjqen jcpjfpwwyt (bkctiwizjs, 23.7 - 48.7) View more | Positive | 21 Oct 2023 | |||
zwweamxqyq(ujfjttjkii) = hmmflmzajc jcpjfpwwyt (bkctiwizjs, 21.1 - 56.3) View more | |||||||
Phase 1 | 32 | Ociperlimab 50 mg | otuqqszijc(uenfyahnqj) = zendaxnngc ithroxehoq (zhrzrruwia ) View more | Positive | 01 Oct 2023 | ||
Ociperlimab 150 mg | otuqqszijc(uenfyahnqj) = khhseidbvu ithroxehoq (zhrzrruwia ) View more |